实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展

doi:10.11904/j.issn.1002-3070.2019.02.016

摘要/Abstract

摘要： 弥漫大B细胞淋巴瘤(DLBCL)是一组高度异质性疾病,具有独特的病理特征和遗传学改变,患者的预后很大程度上取决于此。随着精准医疗的发展,如何更早期的识别出高危患者并予以相关治疗以延长患者的生存时间及提高患者的生存质量尤为重要。近年来,DLBCL预后相关实验室标志物的研究不断取得进展,更有效的预测患者的预后并指导临床治疗。本文将对实验室标志物在DLBCL预后方面的最新研究进展进行综述。

关键词: 淋巴瘤, 大B细胞, 预后

Abstract: Diffuse large B-cell lymphoma(DLBCL)is a group of highly heterogeneous diseases with unique pathological characteristics and genetic changes,and the prognosis of patients depends largely on this.With the development of precision medicine,it is especially important to identify high-risk patients earlier and provides related treatments to prolong the survival time of patients and improves their quality of life.In recent years,DLBCL prognosis-related laboratory markers has progressed to more effectively predict patient prognosis and guides clinical treatment.This review summarizes the recent advances in laboratory markers in the prognosis of DLBCL.

Key words: Lymphoma, Large B-cell, Prognosis

中图分类号:

R733

卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.

LU Jiaoyun, ZHANG Qingyuan. Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 183-187.

参考文献

1 Sehn LH,Scott DW,Chhanabhai M,et al.Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP[J].J Clin Oncol,2011,29(11):1452-1457.
2 Bassig BA,Au WY,Mang O,et al.Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States,2001-2010[J].Cancer Epidemiol,2016,42:15-23.
3 Vaqué JP,Martínez N,Batlle-López A,et al.B-cell lymphoma mutations:improving diagnostics and enabling targeted therapies[J].Haematologica,2014,99(2):222.
4 Nakayama S,Yokote T,Akioka T,et al.Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma,not otherwise specified[J].Blood Adv,2017,1(8):486-493.
5 Wang J,Gao K,Lei W,et al.Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma:correlation with CD163 positive M2 type tumor-associated macrophages,not PD-1 positive tumor-infiltrating lymphocytes[J].Oncotarget,2016,8(3):5414-5425.
6 Melchardt T,Troppan K,Weiss L,et al.Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI[J].J Natl Compr Canc Netw,2015,13(12):1501-1508.
7 Shen M,Hu P,Donskov F,et al.Tumor-associated neutrophils as a new prognostic factor in cancer:a systematic review and Meta-analysis[J].PLoS One,2014,9(6):e98259.
8 Manfroi B,Mckee T,Mayol JF,et al.CXCL-8/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-Inducing ligand APRIL[J].Cancer Res,2017,77(5):1097-1107.
9 Schwaller J,Schneider P,Mhawech-Fauceglia P,et al.Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness[J].Blood,2007,109(1):331-338.
10 Porrata LF,Rsitow K,Inwards DJ,et al.Lymphopenia assessed during routine follow-up after immunochemotherapy(R-CHOP)is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma[J].Leukemia,2010,24(7):1343-1349.
11 Manfroi B,Moreaux J,Righini C,et al.Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients[J].Blood Cancer J,2018,8(7):66.
12 Mu S,Ai L,Fan F,et al.Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients:an updated dose-response meta-analysis[J].Cancer Cell Int,2018,18(1):119.
13 Marnell L,Mold C,Clos TWD.C-reactive protein:Ligands,receptors and role in inflammation[J].Clin Immunol,2005,117(2):104-111.
14 Woo HD,Kim K,Kim J.Association between preoperative C-reactive protein level and colorectal cancer survival:a meta-analysis[J].Cancer Causes Control,2015,26(11):1-10.
15 Luo Y,Fu SJ,She DL,et al.Preoperative C-reactive protein as a prognostic predictor for upper tract urothelial carcinoma:A systematic review and meta-analysis[J].Mol Clin Oncol,2015,3(4):924.
16 Huang Y,Feng JF,Liu JS.Prognostic role of serum C-reactive protein in esophageal cancer:a systematic review and meta-analysis[J].Ther Clin Risk Manag,2015,11:89-94.
17 Li N,Tian GW,Wang Y,et al.Prognostic role of the pretreatment C-reactive protein/albumin ratio in solid cancers:a Meta-analysis[J].Sci Rep,2017,7:41298.
18 Wang J,Zhou M,Wang X,et al.Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP[J].Clin Chim Acta,2016,459:150-154.
19 Qin W,Yuan Q,Wu J,et al.Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma:a meta-analysis[J].Leuk Lymphoma,2019,60(2):358-366.
20 Matsumoto K,Fujisawa S,Ando T,et al.Anemia associated with worse outcome in diffuse large B-cell lymphoma patients:a single-center retrospective study[J].Turk J Haematol,2018,35(3):181-184.
21 Hong J,Woo HS,Kim H,et al.Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy[J].Cancer Sci,2015,105(12):1569-1575.
22 Ochi Y,Kazuma Y,Hiramoto N,et al.Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma[J].Ann Hematol,2016,96(1):1-8.
23 Nakayama S,Matsuda M,Adachi T,et al.Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma,not otherwise specified in the R-CHOP era[J].Platelets,2018,26:1-9.
24 Bharadwaj S,Ginoya S,Tandon P,et al.Malnutrition:laboratory markers vs nutritional assessment[J].Gastroenterol Rep,2016,4(4):272-280.
25 Pfensig C,Dominik A,Borufka L,et al.A new application for albumin dialysis in extracorporeal organ support:characterization of a putative interaction between human albumin and proinflammatory cytokines IL‐6 and TNFα[J].Artif Organs,2016,40(4):397-402.
26 Seebacher V,Grimm C,Reinthaller A,et al.The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer[J].Eur J Obstet Gynecol Reprod Biol,2013,171(1):101-106.
27 Bairey O,Shacham-Abulafia A,Shpilberg O,et al.Serum albumin level at diagnosis of diffuse large B-cell lymphoma:an important simple prognostic factor[J].Hematol Oncol,2015,34(4):184-192.
28 Dalia S,Chavez J,Little B,et al.Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era[J].Ann Hematol,2014,93(8):1305-1312.
29 Adly L,Hill D,Sherman ME,et al.Serum concentrations of estrogens,sex hormone-binding globulin,and androgens and risk of breast cancer in postmenopausal women[J].Int J Cancer,2006,119(10):2402-2407.
30 Yao Y,Zhao M,Yuan D,et al.Elevated pretreatment serum globulin albumin ratio predicts poor prognosis for advanced non-small cell lung cancer patients[J].J Thorac Dis,2014,6(9):1261-1270.
31 Oki S,Toiyama Y,Okugawa Y,et al.Clinical burden of preoperative albumin-globulin ratio in esophageal cancer patients[J].Am J Surg,2017,214(5):891-898.
32 Toiyama Y,Yasuda H,Ohi M,et al.Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent[J].Am J Surg,2017,213(1):120-126.
33 Chen Z,Shao Y,Yao H,et al.Preoperative albumin to globulin ratio predicts survival in clear cell renal cell carcinoma patients[J].Oncotarget,2017,8(29):48291-48302.
34 Kim SH,Go SI,Seo J,et al.Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP[J].Leuk Res,2018,71:100-105.
35 Yue W,Liu B,Gao L,et al.The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma[J].Clin Chim Acta,2018,485:316-322.
36 Umino K,Fujiwara SI,Minakata D,et al.Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP[J].Leuk lymphoma,2018,6:1-8.
37 Dlouhy I,Filella X,Rovira J,et al.High serum levels of soluble interleukin-2 receptor(sIL2-R),interleukin-6(IL-6)and tumor necrosis factor alpha(TNF)are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma[J].Leuk Res,2017,59:20-25.
38 Umino K,Fujiwara SI,Ikeda T,et al.Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP[J].Hematology,2017,22(9):521-526.
39 Ma M,Zhao R,Yang X,et al.The clinical significance of Mda-7/IL-24 and C-myb expression in tumor tissues of patients with diffuse large B cell lymphoma[J].Exp Ther Med,2018,16(2):649-656.
40 Moreno MJ,Gallardo A,Novelli S,et al.CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis[J].PLoS One,2018,13(6):e0198789.
41 Wu X,Wang F,Li Y,et al.Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma[J].Oncol Lett,2018,15(6):9725-9734.
42 Ollila TA,Olszewski AJ.Extranodal diffuse large B cell lymphoma:molecular features,prognosis,and risk of central nervous system recurrence[J].Curr Treat Options Oncol,2018,19(8):38.
43 Ishikawa E,Tanaka T,Shimada K,et al.A prognostic model,including the EBV status of tumor cells,for primary gastric diffuse large B-cell lymphoma in the rituximab era[J].Cancer Med,2018,7(7):3510-3520.
44 Lee DY,Kang K,Jung H,et al.Extranodal involvement of diffuse large B-cell lymphoma in the head and neck:An indicator of good prognosis[J].Auris Nasus Larynx,2018[Epub ahead of print].
45 Kleinstern G,Maurer MJ,Liebow M,et al.History of autoimmune conditions and lymphoma prognosis[J].Blood Cancer J,2018,8(8):73.
46 Almansour MM,Alghamdi SA,Alsubaie MA,et al.Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma[J].Infect Agent Cancer,2018,13(1):18.
47 Witte H,Biersack H,Kopelke S,et al.The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma[J].Br J Haematol,2018[Epub ahead of print].
48 Tanimura A,Hirai R,Nakamura M,et al.The prognostic impact of dose-attenuated R-CHOP therapy for elderly patients with diffuse large B-cell lymphoma[J].Intern Med,2018[Epub ahead of print].

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	李雪蓉, 冯洪燕, 周莹, 李超群, 兰晓莉, 卜丽红. 比较¹⁸F-FDG PET/CT显像IHP、Deauville和△SUVmax在恶性淋巴瘤早中期治疗敏感性判定和预后评估中的应用价值[J]. 实用肿瘤学杂志, 2019, 33(2): 160-166.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[9]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[10]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[11]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[12]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[13]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[14]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.
[15]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.